Updates to Statute 1557 that Healthcare Providers Need to Know
Privacy and Healthcare Business Associates with Isabella Porter
State Law Privacy Video Series | Healthcare Entities and Health Data
Gerry Blass on Healthcare Vendor Risk Management
AGG Talks: Technology - In the Balance: Interoperability and Security
Is Your Practice's Marketing HIPAA Compliant?
Relaxed HIPAA Restrictions For Providers Using Telehealth
Compliance Perspectives: Permissible Disclosures under HIPAA, Especially in the Time of COVID-19
Polsinelli Podcasts - Confusion to Clarity on the Future of the 340B Program
Polsinelli Podcast - HIPAA Changes Overview
Last year, the federal Office for Civil Rights (OCR) modified the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule to strengthen protections for reproductive health care information (the “2024 Rule”)....more
In the wake of a recent federal District Court decision, the reproductive health care HIPAA Privacy rules finalized during the Biden Administration have been vacated and plan sponsors should re-evaluate the language included...more
On June 18, 2025, the U.S. District Court for the Northern District of Texas issued an opinion that vacates the 2024 final rule that enhanced privacy protections for protected health information (PHI) related to reproductive...more
The United States Court of Appeals for the Fifth Circuit (the “Court”) vacated a $4,348,000 civil monetary penalty (“CMP”) imposed by the U.S. Department of Health and Human Services’ Office for Civil Rights (“HHS-OCR”) in...more
On January 14, the Fifth Circuit vacated the University of Texas M.D. Anderson Cancer Center’s (M.D. Anderson) $4.3 million fine for HIPAA violations arising from its loss of more than 35,000 individuals’ protected health...more
In what amounts to a victory for the pharmaceutical industry, on October 14, 2015, the U.S. District Court for the District of Columbia vacated the interpretive rule issued by the U.S. Department of Health and Human Services...more
A federal court vacated the Department of Health and Human Services’ (HHS) Orphan Drug Rule that had allowed certain 340B Drug Pricing Program (340B Program) hospital covered entities to receive discounted prices when...more